CoChat

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung function with high mortality within the first 5 years from diagnosis. In 2011–2014, two drugs, pirfenidone and nintedanib, have been approved worldwide for prevention of IPF progression. National IPF-registries have been established in both Finland and Sweden. Our study explored potential differences in the care of IPF in these two countries. Patients included consecutively in the Finnish and Swedish IPF-registries from January 1, 2014 through December 31, 2016 were included in the study. Data on demographics and lung function at the time of inclusion were collected. Access to antifibrotic drugs and data on disease outcomes, mortality and the proportion of patients who underwent lung transplantation, was collected during a 3-year follow up. One-hundred and fifty-two patients from the Finnish and 160 patients from the Swedish IPF-cohorts were included in the study. At inclusion, Finnish patients were significantly older than the Swedish patients (74.6 years vs 72.5 years, p = 0.017). The proportion of non-smokers was significantly higher in the Finnish cohort (41.7% vs 26.9%, p = 0.007). Forced vital capacity (FVC), % of predicted (78.2 vs 71.7 for Finnish and Swedish patients, respectively, p = 0.01) and diffusion capacity for carbon monoxide (DL CO ), % of predicted (53.3 vs 48.2 for Finnish and Swedish patients, respectively, p = 0.002) were significantly higher in the Finnish cohort compared to the Swedish cohort at the time of inclusion. During the 3-year follow up period, 45 (29.6%) Finnish and 111 (69.4%) Swedish patients, respectively, were initiated on treatment with an antifibrotic drug (pirfenidone or nintedanib) ( p < 0.001). When comparing possible determinants of treatment, patients with higher FVC % were less likely to start antifibrotic drugs (OR 0.96, 95%CI 0.93–1.00, p < 0.024). To be resident in Sweden was the main determinant for receiving antifibrotic drugs (OR 5.48, 95%CI 2.65–11.33, p < 0.0001). No significant difference in number of deaths and lung transplantation during the follow up period was found. This study highlights differences concerning how IPF patients are treated in Finland and Sweden. How these differences will influence the long-term outcome of these patients is unknown.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40248-018-0126-7

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Myllarniemi MKM, Kaunisto J, Kelloniemi K, Kankaanranta H, Hodgson U, et al (2014). The Majority Of IPF Patients Are Diagnosed At A Mild Or Moderate Disease Stage In Finland - Baseline Data From The FinnishIPF Study. American Thoracic Society Conference 2014, Am J Respir Crit Care Med 189(A6404). https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A6404 . · doi:10.1164/ajrccm-conference.2014.189.1_meetingabstracts.a6404

Cited by

See all 27

Metadata

Authors
Pesonen, I., Carlson, L., Murgia, N., Kaarteenaho, R., Sköld, C. M., Myllärniemi, M., & Ferrara, G.
Affiliations
  • Karolinska University Hospital (SE)
  • University of Perugia (IT)
  • Oulu University Hospital (FI)
  • University of Helsinki (FI)
Corresponding author
Pesonen, Ida
Venue
Multidisciplinary Respiratory Medicine
Publisher
Mattioli1885
Published
2018-05-14
Volume
13
Issue
1
Pages
14-14
ISSN
  • 1828-695X (ISSN-L)
  • 2049-6958
OpenAlex
W2806388389
Cited by
25
References
23
Citations by year
2026: 1 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 7 · 2020: 6 · 2019: 3
FWCI
3.01
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Multidisciplinary Respiratory Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • Työväentutkimus Vuosikirja (submittedVersion, other-oa)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, cc-by)
Funders
  • Sigrid Juséliuksen Säätiö
  • Hengityssairauksien Tutkimussäätiö
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
idiopathic pulmonary fibrosis, antifibrotic agents, pirfenidone, nintedanib, treatment delay, health care access, lung function, forced vital capacity, diffusion capacity, lung transplantation, mortality, Finland, Sweden, cross-national comparison, smoking status, age at diagnosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries. https://app.cochat.ai/papers/10.1186/s40248-018-0126-7
The paper
Pesonen, I., Carlson, L., Murgia, N., Kaarteenaho, R., Sköld, C. M., Myllärniemi, M., & Ferrara, G. (2018). Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries. Multidisciplinary Respiratory Medicine. https://doi.org/10.1186/s40248-018-0126-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.